Interestingly expansion and regulation of the breast cancer stem cell population directly depend on VEGFR2 expression (Zhao et al., 2014; Farzaneh Behelgardi et al., 2020), and inhibitors against VEGFR1 and VEGFR2 have been designed to suppress tumor growth and under the clinical application. Here, FLT1 is linked to breast cancer.